Galmed Pharmaceuticals Lt... (GLMD)
2.88
0.02 (0.70%)
At close: Jan 14, 2025, 3:59 PM
2.77
-3.94%
Pre-market Jan 15, 2025, 04:16 AM EST
undefined% (undefined)
| Bid | 2.75 |
| Market Cap | 4.78M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 69.72 |
| PE Ratio (ttm) | 0.04 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 3.09 |
| Volume | 7,352 |
| Avg. Volume (20D) | 72,963 |
| Open | 2.94 |
| Previous Close | 2.86 |
| Day's Range | 2.87 - 2.98 |
| 52-Week Range | 2.56 - 23.80 |
| Beta | undefined |
About GLMD
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinica...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 13, 2014
Employees 3
Stock Exchange NASDAQ
Ticker Symbol GLMD
Website https://www.galmedpharma.com
Analyst Forecast
According to 1 analyst ratings, the average rating for GLMD stock is "Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
3 months ago ·
Source
-11.93%
Galmed Pharmaceuticals shares are trading lower. T...
Unlock content with
Pro Subscription
3 months ago ·
Source
+21.74%
Galmed Pharmaceuticals shares are trading higher after the company announced plans to broaden its drug development activities with two additional programs over the next two years.
